Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Valneva ( (VALN) ) just unveiled an update.
Valneva SE announced positive results from its Phase 2 study of the Lyme disease vaccine candidate, VLA15, on September 3, 2025. The study showed a strong immune response and favorable safety profile after a third booster dose, consistent with previous results, highlighting the vaccine’s potential benefits. With no approved human vaccines for Lyme disease, VLA15 is the most advanced candidate in clinical development, with two Phase 3 trials nearing completion. The vaccine targets the outer surface protein A of Borrelia burgdorferi, the bacteria causing Lyme disease, and covers the six most prevalent serotypes in North America and Europe. Valneva’s collaboration with Pfizer aims to address the pressing unmet medical need for Lyme disease vaccination as the disease’s geographic footprint expands.
The most recent analyst rating on (VALN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
Valneva’s overall stock score reflects a mix of positive technical momentum and strategic progress in vaccine development, offset by financial challenges. The company’s strong cash position and revenue growth are promising, but negative profitability and valuation metrics weigh on the score.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company focuses on providing first-, best-, or only-in-class vaccine solutions and has a strong track record of advancing vaccines from early R&D to approvals. Valneva currently markets three proprietary travel vaccines and is developing the only Lyme disease vaccine candidate in advanced clinical development, in partnership with Pfizer.
Average Trading Volume: 70,196
Technical Sentiment Signal: Buy
Current Market Cap: $749.3M
For a thorough assessment of VALN stock, go to TipRanks’ Stock Analysis page.